{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:23:41Z","timestamp":1750357421232},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11886-017-0899-x","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T07:58:41Z","timestamp":1503561521000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacologic Management for Heart Failure and Emerging Therapies"],"prefix":"10.1007","volume":"19","author":[{"given":"Diana H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Ju","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard J.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"899_CR1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association. Circulation. 2017;135:e146\u2013603.","journal-title":"Circulation"},{"key":"899_CR2","doi-asserted-by":"crossref","unstructured":"Selim A, Zolty R, Chatzizisis YS. The evolution of heart failure with reduced ejection fraction pharmacotherapy: what do we have and where are we going? Pharmacol. Ther. 2017.","DOI":"10.1016\/j.pharmthera.2017.03.011"},{"key":"899_CR3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"899_CR4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med"},{"key":"899_CR5","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362:772\u20136.","journal-title":"Lancet"},{"key":"899_CR6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349\u201355.","journal-title":"N Engl J Med"},{"key":"899_CR7","doi-asserted-by":"crossref","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001\u20137.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"899_CR8","doi-asserted-by":"crossref","unstructured":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999;353:9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"899_CR9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"899_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"899_CR11","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, Carson P, D\u2019Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049\u201357.","journal-title":"N Engl J Med"},{"key":"899_CR12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy. JAMA. 2015;314:884.","journal-title":"JAMA"},{"key":"899_CR13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccl.2016.12.008","volume":"35","author":"SS Mitter","year":"2017","unstructured":"Mitter SS, Yancy CW. Contemporary approaches to patients with heart failure. Cardiol Clin. 2017;35:261\u201371.","journal-title":"Cardiol Clin"},{"key":"899_CR14","doi-asserted-by":"crossref","unstructured":"Kitai T, Tang WW. Recent advances in treatment of heart failure. F1000Research. Faculty of 1000 Ltd; 2015;4.","DOI":"10.12688\/f1000research.7022.1"},{"key":"899_CR15","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","volume":"102","author":"PS Jhund","year":"2016","unstructured":"Jhund PS, McMurray JJV. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan. Heart. 2016;102:1342\u20137.","journal-title":"Heart"},{"key":"899_CR16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387\u201395.","journal-title":"Lancet"},{"key":"899_CR17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"\u2022\u2022 McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. This study demonstrates the superiority of LCZ696, a novel angiotensin receptor-neprilysin inhibitor, to enalapril in reducing mortality risks in HFrEF.","journal-title":"N Engl J Med"},{"key":"899_CR18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807\u201316.","journal-title":"Lancet"},{"key":"899_CR19","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","volume":"133","author":"MA Psotka","year":"2016","unstructured":"\u2022\u2022 Psotka MA, Teerlink JR. Ivabradine: role in the chronic heart failure armamentarium. Circulation. 2016;133:2066\u201375. This comprehensive review highlights recent major clinical studies on the use of ivabradine, a novel small molecule inhibitor of the I f , in the management of heart failure.","journal-title":"Circulation"},{"key":"899_CR20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/phar.1556","volume":"35","author":"JE Basaraba","year":"2015","unstructured":"Basaraba JE, Barry AR. Pharmacotherapy of heart failure with preserved ejection fraction. Pharmacother. J Hum Pharmacol Drug Ther. 2015;35:351\u201360.","journal-title":"J Hum Pharmacol Drug Ther"},{"key":"899_CR21","first-page":"670","volume":"32","author":"BA Borlaug","year":"2011","unstructured":"Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J. Oxford University Press. 2011;32:670\u20139.","journal-title":"Eur. Heart J. Oxford University Press"},{"key":"899_CR22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"899_CR23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"899_CR24","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JGF Cleland","year":"2006","unstructured":"Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338\u201345.","journal-title":"Eur Heart J"},{"key":"899_CR25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17:634\u201342.","journal-title":"J Card Fail"},{"key":"899_CR26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. JAMA. 2013;309:781.","journal-title":"JAMA"},{"key":"899_CR27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"899_CR28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","volume":"14","author":"VM Conraads","year":"2012","unstructured":"Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219\u201325.","journal-title":"Eur J Heart Fail"},{"key":"899_CR29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","volume":"114","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397\u2013403.","journal-title":"Circulation"},{"key":"899_CR30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","volume":"5","author":"MM Redfield","year":"2012","unstructured":"Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, et al. PhosphdiesteRasE-5 inhibition to improve CLinical status and EXercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail NIH Public Access. 2012;5:653\u20139.","journal-title":"Circ Heart Fail NIH Public Access"},{"key":"899_CR31","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA"},{"key":"899_CR32","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887\u201398.","journal-title":"N Engl J Med"},{"key":"899_CR33","unstructured":"D\u00edez J, Ruilope LM. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. Eur. Hear. Journal. Cardiovasc. Pharmacother. Oxford University Press; 2016;2:119\u2013130."},{"key":"899_CR34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","volume":"373","author":"JR Teerlink","year":"2009","unstructured":"Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429\u201339.","journal-title":"Lancet"},{"key":"899_CR35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29\u201339.","journal-title":"Lancet"},{"key":"899_CR36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ejhf.830","volume":"19","author":"JR Teerlink","year":"2017","unstructured":"Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail. 2017;19:800\u20139.","journal-title":"Eur J Heart Fail"},{"key":"899_CR37","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","volume":"374","author":"B Zinman","year":"2016","unstructured":"Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374:1092\u20134.","journal-title":"N Engl J Med"},{"key":"899_CR38","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jacc.2009.12.044","volume":"55","author":"R Gao","year":"2010","unstructured":"Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55:1907\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"899_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543784.2016.1123248","volume":"25","author":"LC Liu","year":"2016","unstructured":"Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs. 2016;25:117\u201327.","journal-title":"Expert Opin Investig Drugs"},{"key":"899_CR40","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Solomon SD, Adams KF, Cleland JGF, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388:2895\u2013903.","journal-title":"Lancet"},{"key":"899_CR41","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","volume":"67","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. J Am Coll Cardiol. 2016;67:1444\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"899_CR42","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S1071-9164(96)80062-5","volume":"2","author":"M Tada","year":"1996","unstructured":"Tada M, Toyofuku T. SR Ca(2+)-ATPase\/phospholamban in cardiomyocyte function. J Card Fail. 1996;2:S77\u201385.","journal-title":"J Card Fail"},{"key":"899_CR43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+\u2212ATPase in patients with advanced heart failure. Circulation. 2011;124:304\u201313.","journal-title":"Circulation"},{"key":"899_CR44","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.jacc.2008.03.015","volume":"51","author":"M Gheorghiade","year":"2008","unstructured":"Gheorghiade M, Blair JEA, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent. J Am Coll Cardiol. 2008;51:2276\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"899_CR45","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1161\/CIRCULATIONAHA.105.584441","volume":"112","author":"JC Burnett","year":"2005","unstructured":"Burnett JC. Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation. 2005;112:3544\u20136.","journal-title":"Circulation"},{"key":"899_CR46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jchf.2013.07.003","volume":"1","author":"WYW Chan","year":"2013","unstructured":"Chan WYW, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 infusion in acute decompensated heart failure. JACC Hear Fail. 2013;1:433\u201341.","journal-title":"JACC Hear Fail"},{"key":"899_CR47","first-page":"715","volume":"36","author":"SD Anker","year":"2015","unstructured":"Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J Oxford University Press. 2015;36:715\u201323.","journal-title":"Eur Heart J Oxford University Press"},{"key":"899_CR48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","volume":"18","author":"H Haller","year":"2016","unstructured":"Haller H, Bertram A, Stahl K, Menne J. Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD? Curr Hypertens Rep Springer US. 2016;18:41.","journal-title":"Curr Hypertens Rep Springer US"},{"key":"899_CR49","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"key":"899_CR50","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur. Heart J. Oxford University Press; 2016;37:2105\u20132114."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0899-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0899-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0899-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T18:59:13Z","timestamp":1570042753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0899-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0899-x","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]},"article-number":"94"}}